Cargando…

TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT)

BACKGROUND: Atrial fibrillation (AF) patients with a high risk of stroke are recommended anticoagulation with warfarin. However, the benefit of warfarin is dependent upon time spent within the target therapeutic range (TTR) of their international normalised ratio (INR) (2.0 to 3.0). AF patients poss...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Danielle E, Xuereb, Christian Borg, Pattison, Helen M, Lip, Gregory YH, Lane, Deirdre A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Study protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887377/ https://www.ncbi.nlm.nih.gov/pubmed/20487528 http://dx.doi.org/10.1186/1471-2261-10-21

Ejemplares similares

Educational Intervention Improves Anticoagulation Control in Atrial Fibrillation Patients: The TREAT Randomised Trial
por: Clarkesmith, Danielle E., et al.
Publicado: (2013)

Developing a Complex Educational–Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation
por: Clarkesmith, Danielle E., et al.
Publicado: (2016)

Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry
por: Liang, Hai-Feng, et al.
Publicado: (2019)

Stroke and Bleeding Risk in Atrial Fibrillation
por: Senoo, Keitaro, et al.
Publicado: (2014)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019)

Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis
por: Lane, Deirdre A., et al.
Publicado: (2018)

Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials
por: Proietti, Marco, et al.
Publicado: (2016)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
por: Nelson, Winnie W., et al.
Publicado: (2014)

Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand
por: Krittayaphong, Rungroj, et al.
Publicado: (2020)

Patients' Perceptions of Atrial Fibrillation, Stroke Risk, and Oral Anticoagulation Treatment: An International Survey
por: Lane, Deirdre A., et al.
Publicado: (2018)

Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic
por: Papala, Michelle, et al.
Publicado: (2021)

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022)

Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]
por: Mant, Jonathan WF, et al.
Publicado: (2003)

How Well Does the Target INR Level Maintain in Warfarin-Treated Patients with Non-ValvularAtrial Fibrillation?
por: Kim, Jun Hyung, et al.
Publicado: (2009)

Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin
por: Luengsupabul, Sirote, et al.
Publicado: (2020)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Suboptimal oral anticoagulant treatment among Chinese non-valvular atrial fibrillation patients: the Nanchang Atrial Fibrillation Project
por: Xiong, Qinmei, et al.
Publicado: (2016)

The management of anticoagulants in patients with atrial fibrillation and history of falls or risk of falls: protocol for a systematic review and meta-analysis
por: Galvain, Thibaut, et al.
Publicado: (2022)

Effects of structured patient education on knowledge level and INR control of patients receiving warfarin: Randomized Controlled Trial
por: Baysal, Ebru, et al.
Publicado: (2018)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Anticoagulation in older people with atrial fibrillation moving to care homes: a data linkage study
por: Ritchie, Leona A, et al.
Publicado: (2022)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
por: de Padua Mansur, Antonio, et al.
Publicado: (2012)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

Veterans Perceptions of Satisfaction and Convenience with Anticoagulants for Atrial Fibrillation: Warfarin versus Direct Oral Anticoagulants
por: Mull, Hillary J, et al.
Publicado: (2020)

Management of atrial fibrillation
por: Kakar, Puneet, et al.
Publicado: (2007)

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study
por: Liu, Shin-Huei, et al.
Publicado: (2023)

The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study
por: Gemmati, Donato, et al.
Publicado: (2016)

Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists
por: Zulkifly, Hanis H., et al.
Publicado: (2023)

Impact of serum albumin levels on supratherapeutic PT-INR control and bleeding risk in atrial fibrillation patients on warfarin: A prospective cohort study
por: Kawai, Mayumi, et al.
Publicado: (2019)

Warfarin/herbal drink interaction: Elevated INR: case report
Publicado: (2021)

A CONTROVERSY: WARFARIN FAILURE IN COVID-19 WITH SUPRATHERAPEUTIC INR
por: Ur Rahman, Saad
Publicado: (2023)

Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation—The EWA study
por: Jaakkola, Samuli, et al.
Publicado: (2017)

Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
por: Pundi, Krishna N., et al.
Publicado: (2021)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
por: Yoo, Seo Yeon, et al.
Publicado: (2022)

The Atrial Fibrillation Better Care pathway for managing atrial fibrillation: a review
por: Stevens, David, et al.
Publicado: (2021)

The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2019)

Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal
por: Lane, Deirdre A, et al.
Publicado: (2020)

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
por: Larsen, Torben Bjerregaard, et al.
Publicado: (2016)

Comparison of the effects of different treatment protocols on mortality in patients presenting with an INR≥10 due to warfarin-associated over-anticoagulation
por: İslam, Mehmet Muzaffer, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nasr9n8ser60qaapkjj6qbnh19